Clinical Trial Detail

NCT ID NCT02483247
Title A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors Boston Biomedical, Inc
Indications

Advanced Solid Tumor

Therapies

Paclitaxel

Doxorubicin

Capecitabine

Nivolumab

Sunitinib

Pembrolizumab

BBI503

Age Groups: adult

No variant requirements are available.